For the acute treatment of migraine in adults. Not for preventive treatment.
The Nurtec ODT Patient Support Program
is committed to helping your eligible
patients afford
their medication. Use the Formulary Lookup Tool to learn about coverage in your area.
Actual Nurtec ODT Patient
More than 220 million insured individuals
have access to Nurtec ODT*
Nurtec ODT is the only preferred oral CGRP receptor antagonist on Anthem's national commercial formulary.*
Nurtec ODT is the exclusive oral CGRP receptor antagonist on the BlueCross BlueShield Federal Employee Program commercial formulary.*
Nurtec ODT is the only preferred CGRP receptor antagonist on TRICARE's formulary.*
Patients can download and activate a card to get started today via 2 easy ways:
This offer is invalid for patients without commercial insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program.
†Per 8-tablet prescription. See .
‡Message and data rates may apply. Patients may receive approximately 5 messages a month.
For information, including our Privacy Policy and Terms & Conditions,
please visit www.Nurtec.com/copay-terms. Once
registered,
text HELP to 267-89 for more information. Text STOP to end.
We're committed to helping people with migraine get access to Nurtec ODT. If your patients are experiencing financial hardship or have limited or no insurance coverage, they can enroll in the Biohaven Patient Assistance Program, which provides assistance to those who qualify.
Download formPatients with commercial insurance may be able to pay as little as $0 per month. This offer is invalid for patients without commercial insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. See full Terms & Conditions for eligibility and restrictions.
Reference: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc.
Dosing
Resources
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.
Please click here for full Prescribing Information.